Dosing and effect of C5a antagonist with ANCA-associated vasculitis
US-12350263-B2 · Jul 8, 2025 · US
This page is not indexed by search engines while we improve data quality.
Hillson Jan patents
Hillson Jan is listed as an inventor on 8 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Hillson Jan |
| Total patents | 8 |
| First publication | Dec 12, 2019 |
| Latest publication | Jul 8, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
FcRn Antibodies and Methods of Use Thereof
US-2023049725-A1 · Feb 16, 2023 · US
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
US-2022296576-A1 · Sep 22, 2022 · US
Methods and uses of variant icos ligand (icosl) fusion proteins
US-2022218785-A1 · Jul 14, 2022 · US
FcRn antibodies and methods of use thereof
US-11345751-B2 · May 31, 2022 · US
Dosing and effect of C5a antagonist with ANCA-associated vasculitis
US-11191756-B2 · Dec 7, 2021 · US
FcRn Antibodies and Methods of Use Thereof
US-2021238275-A1 · Aug 5, 2021 · US
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
US-2019374524-A1 · Dec 12, 2019 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Chemocentryx Inc | 4 |
| Momenta Pharmaceuticals Inc | 2 |
| Momenta Pharmaceuticals Inc | 1 |
| Alpine Immune Sciences Inc | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P9/00 | 7 |
| A61K2039/505 | 7 |
| A61K2300/00 | 5 |
| A61K31/451 | 4 |
| A61K31/573 | 4 |